MariTide phase 3 results (MARITIME-1): what to expect
Reviewed 14 sourcesPublished by PepVault
MariTide's phase 3 MARITIME-1 trial: what it tests, what phase 2 showed, the bar Zepbound and Wegovy set, and when the 72-week results are expected.

- Last reviewed
- Sources
- 14
- Questions
- 6
- Compounds
- 3
The short answer
MARITIME-1 has not reported as of November 20, 2026. The 72-week phase 3 trial tests three doses of Amgen's MariTide, a once-a-month shot, against placebo in 3,853 adults with obesity and no diabetes. The registry estimates primary completion for January 21, 2027. The bars to clear at 72 weeks: tirzepatide's 20.9% and high-dose Wegovy's 18.8%, with fewer people stopping for side effects than the 11% in phase 2's step-up arms.
Evidence: One randomised phase 2 trial in 592 people (NEJM 2025) and a phase 1 trial in people, with the phase 3 design from ClinicalTrials.gov and Amgen's releases; MARITIME-1 and MARITIME-2 have not reported, and MariTide is investigational.

What is MARITIME-1 testing?
MARITIME-1 is MariTide's lead phase 3 weight-loss trial, and its result will show whether one injection every four weeks can keep up with the weekly drugs. Amgen enrolled 3,853 adults, randomly assigned to a high, medium or low dose of maridebart cafraglutide (MariTide) or to placebo, a dummy shot, for 72 weeks. It is double-blind: neither the participants nor the investigators know who gets what1.
| Design | MARITIME-1 | MARITIME-2 |
|---|---|---|
| Registry number | NCT06858839 | NCT06858878 |
| Who | Adults with a BMI of 30 or more, or 27 to 30 with a weight-related condition such as high blood pressure or sleep apnea; no diabetes | Adults with type 2 diabetes and a BMI of 27 or more |
| People enrolled | 3,853 | 1,105 |
| Arms | MariTide high, medium or low dose, or placebo | MariTide high, medium or low dose, or placebo |
| Length | 72 weeks | 72 weeks |
| Primary endpoint | Percent change in body weight at week 72 | Percent change in body weight at week 72 |
| Primary completion (registry estimate) | January 21, 2027 | January 21, 2027 |
Both rows come from the ClinicalTrials.gov records, read on November 20, 202612. The primary endpoint is the one result a trial is built to answer. MARITIME-2 also measures blood sugar (HbA1c, the three-month average), but as a secondary endpoint2.
Every MariTide arm opens the same way. Amgen states that participants start at 21 mg, step to 35 mg and then 70 mg over eight weeks, and then move to their assigned target dose5. The registry does not name the three target amounts1, and neither has Amgen. They are trial doses, not a regimen.
The drug itself is built unusually: a full antibody that blocks the GIP receptor, carrying two GLP-1 peptides that switch the GLP-1 receptor on3. The antibody is what lets it last: in phase 1 its half-life was about 14 to 16 days for the active form and 21 to 24 days for the antibody overall9. PepVault's guide to monthly GLP-1 shots covers how it works in full.
Try it
How MariTide builds up
An estimate from a half-life of about 15 days, one dose a week for four weeks. The shape of the level, not a measurement.

What did MariTide's phase 2 trial show?
Phase 2, published in the New England Journal of Medicine in 2025, gave 592 people MariTide or placebo for 52 weeks3. In the 465 people without diabetes, average weight loss counting everyone, including those who stopped the drug, ran from 12.3% to 16.2% across the doses, against 2.5% on placebo3. Counting only those who kept taking it, the range was 16.3% to 19.9%, against 2.6%5.
Two details matter for phase 3. First, Amgen reported no weight-loss plateau by week 524, so a 72-week trial gives the curve 20 more weeks to fall. Second, in the 127 people with type 2 diabetes, weight fell 8.4% to 12.3% and HbA1c fell 1.2 to 1.6 points, against 1.7% and a 0.1-point rise on placebo3. That is the group MARITIME-2 now tests at full size.
Phase 2 tested 140, 280 and 420 mg every four weeks, 420 mg every eight weeks, and two arms that climbed to 420 mg over four or twelve weeks3. In a second year, people who had lost at least 15% moved to a lower monthly dose or a quarterly shot, and Amgen reported that the large majority kept their loss for another 52 weeks11; it has not given the numbers. Phase 3 tests the same idea next: the MARITIME-1 extension, now enrolling, moves people who finish the trial to monthly, every-eight-week or quarterly dosing10.
How does MariTide compare with Zepbound and Wegovy so far?
The fair comparison is the measure that counts everyone, including people who stopped, because that is the figure each of these trials led with. On that measure, MariTide's best phase 2 arm, 16.2%, sits above Wegovy's 2.4 mg dose and below tirzepatide 15 mg and Wegovy's newer 7.2 mg dose, after a shorter trial3678.
| Trial | Drug and dose | Length | Average weight loss, everyone counted | Placebo | Stopped for side effects |
|---|---|---|---|---|---|
| MariTide phase 2345 | 140 to 420 mg, every 4 or 8 weeks | 52 weeks | 12.3% to 16.2% | 2.5% | About 11% in the step-up arms; up to 7.8% for stomach side effects, more in arms with no step-up |
| SURMOUNT-16 | Tirzepatide 15 mg weekly (Zepbound) | 72 weeks | 20.9% | 3.1% | 6.2%, against 2.6% on placebo |
| SURMOUNT-16 | Tirzepatide 5 mg weekly | 72 weeks | 15.0% | 3.1% | 4.3% |
| STEP 178 | Semaglutide 2.4 mg weekly (Wegovy) | 68 weeks | 14.9% | 2.4% | 4.5% for stomach side effects, against 0.8%; 6.8% for any, against 3.2%, across the label's trials |
| STEP UP, Wegovy label Study 88 | Semaglutide 7.2 mg weekly (Wegovy) | 72 weeks | 18.8% | 3.9% | 5.4%, against 1% on placebo |
Lengths differ: phase 2 stopped at 52 weeks, and MARITIME-1 runs 72, the same as SURMOUNT-1 and STEP UP. Semaglutide 2.4 mg's 6.8% comes from the Wegovy label's pooled weight trials, not STEP 1 alone8.
PepVault charts every weigh-in from your starting weight, so you can set your own change next to these trial averages. Track your weight in PepVault
What would count as a good MARITIME-1 result?
Amgen has set no public target, so here is PepVault's reading, written before the result so it cannot bend to fit it. The comparator trials set the bars, and MARITIME-1 reports the same week-72 measures16.
- Weight, top dose, everyone counted: about 21% or more matches tirzepatide 15 mg at the same week6. About 19% to 20% beats high-dose Wegovy's 18.8% at week 728. Between 15% and 19% sits with Wegovy 2.4 mg (14.9% at week 687), with monthly dosing as its edge. Under 15% falls short of the weekly shots.
- Share losing 20% or more: a secondary endpoint of MARITIME-11. On tirzepatide 15 mg it was 57%, against 3% on placebo6.
- Stopping for side effects: about 7% or less would put MariTide level with the weekly drugs (6.2% on tirzepatide 15 mg; 6.8% on Wegovy 2.4 mg and 5.4% on 7.2 mg)68. That is the number to watch, because phase 2's step-up arms lost about 11% to side effects4.
- The first weeks: how many people vomit after the opening doses, the figure the lower 21 mg start was built to bring down5.
Tolerability was phase 2's talking point. Nausea and vomiting came mainly with the first dose and were much less common when the dose was stepped up4. Amgen then ran a phase 1 study of lower starts: with 21 mg, then 70 mg, then 350 mg, 24.4% vomited at some point and no one stopped for stomach side effects5. Phase 3's 21, 35, 70 mg climb came out of that work5.
Commonly reported: in the phase 2 step-up arms, nausea that came in episodes and settled within a median of about six days, and vomiting that lasted one to two days, mostly after the first dose4.
When will MARITIME-1 results come out?
The registry's primary completion date, January 21, 2027, is an estimate of when the last participant reaches the week-72 weigh-in, not a results date; the full study runs to an estimated April 16, 202712. Amgen has not stated when it will report: its November 3, 2026 quarterly release lists both trials as ongoing with no readout date10.
Phase 2 shows the usual pace. Its primary completion was October 8, 202412, Amgen's topline release followed on November 26, 20244, and the full results came at the American Diabetes Association meeting and in the journal on June 23, 202553. The same gaps would put a MARITIME-1 topline in early 2027, as an expectation, not a promise.
| Date | What could happen |
|---|---|
| January 21, 2027 | Primary completion, the registry's estimate for both trials12 |
| Early 2027 | An Amgen topline press release, if phase 2's pace holds (PepVault's expectation) |
| May 18 to 21, 2027 | European Congress on Obesity, Munich14 |
| June 18 to 21, 2027 | American Diabetes Association Scientific Sessions, Washington, D.C.13 |
The ADA's regular abstract deadline, January 5, 2027, falls before the registry's primary completion date13; a full presentation that June would depend on the meeting's late-breaking slots or a journal paper.
PepVault can schedule a shot every four weeks today, as a cycle of one day on and 27 days off: the reminder comes on the day it is due, and the log keeps every shot with its date. Set reminders in PepVault
Has MARITIME-1 reported yet?
Not reported as of November 20, 2026. When Amgen releases the topline, this section will carry, for each of the three doses and placebo: the average weight change at week 72 counting everyone and counting only those who stayed on the drug, the share reaching 10%, 15% and 20%, the rate of stopping for side effects, and the target doses, which are still unnamed. MARITIME-2's numbers, including HbA1c, will sit beside them2.
MariTide is investigational and approved nowhere. For the drug itself, PepVault's MariTide page in the library covers its mechanism, half-life and trial timeline. The Zepbound and Wegovy bars above each have their own study page in PepVault's research section: SURMOUNT-1, STEP 1 and STEP UP.
Sources
- ClinicalTrials.gov NCT06858839. MARITIME-1: maridebart cafraglutide in adults without type 2 diabetes who have obesity or are overweight (phase 3; sponsor Amgen). Record updated September 17, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT06858878. MARITIME-2: maridebart cafraglutide in adults with type 2 diabetes who have obesity or are overweight (phase 3; sponsor Amgen). Record updated December 31, 2025. clinicaltrials.gov
- Jastreboff AM et al. Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial. N Engl J Med. 2025;393(9):843-857. PubMed 40549887
- Amgen. Amgen announces robust weight loss with MariTide in people living with obesity or overweight at 52 weeks in a phase 2 study. Press release, November 26, 2024. amgen.com
- Amgen. Results from Amgen's phase 2 obesity study of monthly MariTide presented at the American Diabetes Association 85th Scientific Sessions. Press release, June 23, 2025. amgen.com
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Wegovy (semaglutide) prescribing information, sections 6.1 and 14.2 (Studies 8 and 9, the 7.2 mg dose). Novo Nordisk. DailyMed, version 19, June 2026. dailymed.nlm.nih.gov
- Véniant MM et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6(2):290-303. PubMed 38316982
- Amgen. Amgen reports third quarter 2026 financial results. Press release, November 3, 2026. amgen.com
- Amgen. Amgen reports fourth quarter and full year 2025 financial results. Press release, February 3, 2026. amgen.com
- ClinicalTrials.gov NCT05669599. Phase 2 study of AMG 133 (maridebart cafraglutide) in adults with obesity, with or without type 2 diabetes (sponsor Amgen). Primary completion October 8, 2024. clinicaltrials.gov
- American Diabetes Association. Scientific Sessions: save the date, Washington, D.C., June 18-21, 2027. professional.diabetes.org
- ECO2027: the 34th European Congress on Obesity, Munich, 18-21 May 2027 (congress site). eco2027.org
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.